Bottom line
IBB vs IBBQ: the short answer
IBB (iShares Biotechnology ETF) and IBBQ (Invesco Nasdaq Biotechnology ETF) share a meaningful slice of their top holdings — about 56% by weight.
IBBQ is cheaper at 0.19% vs 0.44% — a difference of $25 a year per $10,000 invested.
Over one year, IBB returned +28.0% vs −0.6% for IBBQ (reporting dates differ).
Updated Nov 19, 2026
IBB vs IBBQ side by side
| IBB | IBBQ | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 0.19% |
| Annual cost per $10k | $44 | $19 |
| 10-yr cost on $10k (prospectus) | $555 | $242 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +28.0% | −0.6% |
| 5-yr return (annualized) | +2.5% | — |
| 10-yr return (annualized) | +4.4% | — |
| Best quarter | +26.8% | +12.0% |
| Worst quarter | −22.9% | −11.7% |
| Net assets (fund) | $5.9B | $67.4M |
| Number of holdings | 254 | 261 |
| Portfolio turnover | 27% | 17% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | IBBQ | Difference |
|---|---|---|---|
| 2024 | −2.4% | −0.6% | −1.8% |
| 2023 | +3.6% | +4.5% | −0.9% |
| 2022 | −13.6% | −10.2% | −3.3% |
Source: Fund prospectus bar charts
Holdings overlap
14 of IBB's top 25 holdings also appear in IBBQ's top 25.
| Holding | IBB | IBBQ |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 7.38% |
| Gilead Sciences, Inc. | 7.52% | 7.39% |
| Amgen, Inc. | 7.50% | 7.10% |
| Regeneron Pharmaceuticals, Inc. | 5.70% | 5.08% |
| Alnylam Pharmaceuticals, Inc. | 5.68% | 3.19% |
| Argenx SE | 3.15% | 1.89% |
| Insmed, Inc. | 2.95% | 1.83% |
| Biogen, Inc. | 2.03% | 2.29% |
| United Therapeutics Corp. | 1.82% | 1.94% |
| Incyte Corp. | 1.62% | 1.53% |
| Illumina, Inc. | 1.41% | 1.98% |
| Neurocrine Biosciences, Inc. | 1.34% | 1.26% |
| Exelixis, Inc. | 1.07% | 1.04% |
| Moderna, Inc. | 0.88% | 1.48% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
IBBQ top 10
- Invesco Private Prime Fund — 14.20%
- Gilead Sciences, Inc. — 7.39%
- Vertex Pharmaceuticals Inc. — 7.38%
- Amgen Inc. — 7.10%
- Invesco Private Government Fund — 5.48%
- Regeneron Pharmaceuticals, Inc. — 5.08%
- Alnylam Pharmaceuticals, Inc. — 3.19%
- Revolution Medicines, Inc. — 2.48%
- Biogen Inc. — 2.29%
- Illumina, Inc. — 1.98%
FAQ
What is the difference between IBB and IBBQ?
Which is cheaper, IBB or IBBQ?
Should I own both IBB and IBBQ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.